Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T16:17:14.105Z.
Calculation as of: 2026-10-06T16:17:14.105Z.
Quote observation: 2026-10-06T16:14:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a2c27257439ebc7e0324c407d6ec5b5d27bfaa5dcb56832ff3962ee146363265
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$108.87M
PS Ratio
N/A
TTM Avg
2.32
3Y Avg
2.32
5Y Avg
2.32
Market Cap
$109.37M
PS Ratio
N/A
TTM Avg
46.19
3Y Avg
46.23
5Y Avg
46.23
Market Cap
$107.65M
PS Ratio
N/A
TTM Avg
119.38
3Y Avg
60.79
5Y Avg
244.46
Market Cap
$110.11M
PS Ratio
65.93
TTM Avg
60.78
3Y Avg
38.49
5Y Avg
33.17
Market Cap
$111.02M
PS Ratio
3.55
TTM Avg
1.84
3Y Avg
1.24
5Y Avg
1.12
Market Cap
$112.03M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunic, Inc. (IMUX) | $108.82M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $108.87M | N/A | 2.32 | 2.32 | 2.32 |
| Outlook Therapeutics, Inc. (OTLK)vs › | $109.37M | N/A | 46.19 | 46.23 | 46.23 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.65M | N/A | 119.38 | 60.79 | 244.46 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $110.11M | 65.93 | 60.78 | 38.49 | 33.17 |
| Apyx Medical Corporation (APYX)vs › | $110.75M | 1.90 | 2.94 | 1.80 | 3.05 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $111.02M | 3.55 | 1.84 | 1.24 | 1.12 |
| BGM Group Ltd. (BGM)vs › | $111.52M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $112.03M | N/A | N/A | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $112.48M | 3.62 | 3.79 | 7.32 | 10.74 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-11 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
